Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utomilumab and ISA101b in HPV+ Oropharyngeal Cancer
NCT03258008Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2018
- Primary completion
- Nov 2021
- Modality
- Peptides, Peptide-based Cancer Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utomilumab and SLP-HPV-01 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 9 weeks. Started Apr 2018; status: terminated.
02
Drugs
utomilumabSLP-HPV-01
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03258008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258008.